MediBeacon ® Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence ...
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The transdermal GFR (tGFR) methodology has ...
ST. LOUIS, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced ...
St. Louis-based MediBeacon completed a clinical study on subjects with impaired kidney function. Here’s what you should know. 1. Biolase conducted the study at Washington University in St. Louis.
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement of ...
On February 10, 2026, INNOVATE Corp. reported that MediBeacon’s peer-reviewed article on its transdermal glomerular filtration rate (tGFR) technology was named one of five 2025 Editors’ Choice ...
The MediBeacon ® Transdermal GFR System (TGFR) is intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring ...
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results